Treatment for Breast Cancer to take a New Turn

by Medindia Content Team on  July 14, 2006 at 2:09 PM Drug News
RSS Email Print This Page Comment bookmark
Font : A-A+

Treatment for Breast Cancer to take a New Turn
Post Menopausal women with early breast cancer who have been receiving the 30-year-old tamoxifen treatment can now change to a more modern therapy with the drug, Arimidex under a new European licence granted to drug firm AstraZeneca.

The company AstraZeneca has stated that Arimidex, an aromatase inhibitor, will be made available to women who have already received a partial course of tamoxifen.The license for this switch over has been granted in Britain, Portugal, Germany, Spain and Italy.

Clinical research has revealed that Arimidex reduces the risk of return of breast cancer by an additional 26 percent on comparing with tamoxifen.

Thus far, Arimidex was only licensed for use immediately after breast cancer surgery, in patients who have been newly diagnosed with the disease. With the new licence Arimidex has become the first aromatase inhibitor to be approved in Europe for both primary use and subsequent to two to three years of tamoxifen.

Other rival companies Novartis AG and Pfizer Inc also make aromatase inhibitors.


Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Women and Cancer Breast Biopsy Pagets disease of the breast Mastitis Cancer and Homeopathy Breast Cancer Facts Cancer Facts Cancer Breasts - Structures and Types Breast Lumps 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement
Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

Advertisement

News Category

News Archive